Tenaya Therapeutics financials
$0.5931+0.56%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$93.3M | -$115.9M | -$131.2M | -$125.6M | -$72.8M |
| Net income | -$90.6M | -$111.1M | -$124.1M | -$123.7M | -$72.7M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-0.59 | $-1.31 | $-1.68 | $-2.76 | $-4.10 |
| EBITDA | -$84.9M | -$107.5M | -$122.5M | -$116.9M | -$68.7M |
| Operating cash flow | -$68.3M | -$90.5M | -$102.1M | -$104.4M | -$60.8M |
| Free cash flow | -$68.9M | -$91.5M | -$103.3M | -$125.1M | -$85.9M |
| Diluted shares | 153.0M | 84.8M | 73.8M | 44.8M | 17.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $100.5M | $4.3M | $45.7M | $95.3M | $38.1M |
| Short-term investments | $0.00 | $57.1M | $59.0M | $91.3M | $213.2M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $146.9M | $119.9M | $170.5M | $278.9M | $314.2M |
| Total liabilities | $23.7M | $27.1M | $31.1M | $35.6M | $35.7M |
| Shareholders' equity | $123.3M | $92.9M | $139.4M | $243.4M | $278.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology